Generic Ozempic Is Arriving. The Real Test Is Whether Patients Can Afford It

A new Canadian analysis suggests large price cuts could make semaglutide-based diabetes care far more cost-effective for high-risk patients. Canada has approved several generics, but the study models hypothetical discounts, while supply disruption means regulatory approval may not translate into immediate access.